SOFW SOFWAVE MEDICAL LTD

Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer

Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer

SAN CLEMENTE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced the appointment of James Bartholomeusz to the newly created position of Chief Innovation Officer. Mr. Bartholomeusz is a medical aesthetics expert and industry veteran with more than 20 years of experience. He will lead global product innovation, development, and go-to market strategies for new product launches.

“We are delighted to have James join Sofwave at this important stage of accelerated growth, product innovation and global expansion. His past leadership and track record in developing and launching new products includes driving the innovation and roll-out of groundbreaking body contouring technologies, leading-edge energy-based devices, and sophisticated skin treatment solutions, most notably the world’s first fractional RF device,” noted Louis Scafuri, CEO of Sofwave Medical. “We believe James’ relentless pursuit of innovation and excellence has positioned him at the forefront of the medical aesthetics industry. His past accolades serve as testament to his desire to redefine standards of care with a clear focus on long term patient experience. We look forward to the positive impact of James’ leadership, vision and expertise, as we strive to set new treatment innovation benchmarks in our industry.”

Commenting on his appointment, Mr. Bartholomeusz said, “I am honored to join Sofwave and have been impressed with the rapid adoption, acceptance, and growing reputation of the Company’s innovative SUPERB™ technology. Having helped develop and launch some of the industry’s most popular and effective conventional energy-based skin treatment solutions. I look forward to collaborating with the team to bring the very best, transformative non-invasive skin treatment solutions to the market and accelerate new product launches and market penetration for Sofwave products.”

Mr. Bartholomeusz joins Sofwave after his previous role as chief technology officer (CTO) at Lutronic, where he was responsible for developing and executing an ambitious 5-year product roadmap and growth strategy that included various industry defining products like DermaV before Lutronic was acquired by private equity in August of 2023. Prior to Lutronic Mr. Bartholomeusz served Syneron-Candela as Global Vice President of Product Development.

About Sofwave Medical

 has implemented an innovative approach to wrinkle reduction, lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue, the short-term improvement in the appearance of cellulite, improvement of skin laxity on upper arms and treatment of acne scars, providing physicians with smart yet simple, effective, and safe aesthetic solutions for their patients. Contact: 

Investor Contact:

Brian Ritchie

LifeSci Advisors LLC

(212) 915-2578



EN
12/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SOFWAVE MEDICAL LTD

 PRESS RELEASE

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Ful...

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2025 Topline Financial Results SAN CLEMENTE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced preliminary financial results for the fourth quarter and full fiscal year, for the period ended December 31, 2025. Preliminary Financial Results Fourth quarter 2025 revenue is expected to total between $28.6 million and $28.9 million, as compared to approximately $1...

 PRESS RELEASE

Sofwave Medical Reports Third Quarter 2025 Financial Results and Busin...

Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights —  Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7%  — Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth — First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1% — First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period — Approximately 667,00 pulse treatments administered...

 PRESS RELEASE

Sofwave to Participate in Upcoming November Investor Conferences

Sofwave to Participate in Upcoming November Investor Conferences SAN CLEMENTE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that management will participate in the following investor conferences: Stifel 2025 Healthcare ConferencePresentation Format: Corporate overviewPresentation Date: Wednesday, November 12, 2025Presentation Time: 10:40 a.m. ETWebcast: Jefferies London Healthcare Conference Presentation Format: Corporate overviewPresentation Date: ...

 PRESS RELEASE

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit SAN CLEMENTE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Virtual Private MedTech Summit on October 1st, 2025. About Sofwave Medical has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology...

 PRESS RELEASE

Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Stand...

Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Standalone EMS Device For Comprehensive Multi-Body Area Muscle Strengthening and Firming The Pure Impact VIP™ standalone device represents a major extension of the Pure Impact™ product line and introduces an all-in-one independent unitStandalone device is launched with an enhanced Pure Impact™ feature set which provides comprehensive muscle strengthening programs that focus on multiple body areas including the: abdomen, arms, thighs, and buttocks and enables simultaneous treatment of 6 muscle groupsIn the recent McKinsey Life ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch